相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Association of loop diuretics use and dose with outcomes in outpatients with heart failure: a systematic review and meta-analysis of observational studies involving 96,959 patients
Chris J. Kapelios et al.
HEART FAILURE REVIEWS (2022)
Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Volker Vallon et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 83 (2021)
Effect of furosemide on body composition and urinary proteins that mediate tubular sodium and sodium transport-A randomized controlled trial
Mose Frank Holden et al.
PHYSIOLOGICAL REPORTS (2021)
Physiological and Transcriptomic Changes in the Hypothalamic-Neurohypophysial System after 24 h of Furosemide-Induced Sodium Depletion
Sabrina G. Dutra et al.
NEUROENDOCRINOLOGY (2020)
The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease
Ken Ohara et al.
DIABETOLOGY & METABOLIC SYNDROME (2020)
The cellular basis of distinct thirst modalities
Allan-Hermann Pool et al.
NATURE (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume
Takahiro Masuda et al.
PHYSIOLOGICAL REPORTS (2020)
Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
Anja Schork et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of 3% saline and furosemide on biomarkers of kidney injury and renal tubular function and GFR in healthy subjects - a randomized controlled trial
F. H. Mose et al.
BMC NEPHROLOGY (2019)
Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
Claire C. J. Dekkers et al.
DIABETES OBESITY & METABOLISM (2019)
Antidiuretic Hormone and Serum Osmolarity Physiology and Related Outcomes: What Is Old, What Is New, and What Is Unknown?
Mehmet Kanbay et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology
Wilfried Mullens et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan
Ken Ohara et al.
NEPHROLOGY (2019)
Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment - Results From the K-STAR Study
Takayuki Inomata et al.
CIRCULATION JOURNAL (2018)
Functional implications of sexual dimorphism of transporter patterns along the rat proximal tubule: modeling and analysis
Qianyi Li et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2018)
Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat
Takahiro Masuda et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2018)
Prognostic Impact of Loop Diuretics in Patients With Chronic Heart Failure - Effects of Addition of Renin-Angiotensin-Aldosterone System Inhibitors and β-Blockers
Masanobu Miura et al.
CIRCULATION JOURNAL (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Everything we always wanted to know about furosemide but were afraid to ask
Xiaohua Huang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2016)
Tubular Transport in Acute Kidney Injury: Relevance for Diagnosis, Prognosis and Intervention
Volker Vallon
NEPHRON (2016)
Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention
Takahiro Masuda et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2014)
Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences
Ivan Sabolic et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2012)
Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin-Nicotinamide-Induced Mildly Diabetic Mice
Atsuo Tahara et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2012)
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
Atsuo Tahara et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2012)
Evaluation of bioimpedance spectroscopy for the measurement of body fluid compartment volumes in rats
Lufei Hu et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2012)
Chronic Hyperosmotic Stress Converts GABAergic Inhibition into Excitation in Vasopressin and Oxytocin Neurons in the Rat
Jeong Sook Kim et al.
JOURNAL OF NEUROSCIENCE (2011)
Relation of loop diuretic dose to mortality in advanced heart failure
Shervin Eshaghian et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Role of vasopressin in the management of septic shock
GM Mutlu et al.
INTENSIVE CARE MEDICINE (2004)
Furosemide, sodium appetite, and ingestive behavior
RF Lundy et al.
PHYSIOLOGY & BEHAVIOR (2003)
分享论文
